Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 97, Issue 1, 2012, Pages e9-e12

  Shirakawa, Jun ^a   Togashi, Yu ^a   Tajima, Kazuki ^a   Orime, Kazuki ^a   Kikuchi, Kaori ^a   Miyazaki, Takashi ^a   Sato, Koichiro ^a   Kimura, Mari ^a   Goshima, Yoshio ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

EGFR; PAI 1; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPID;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; ASIAN; BLOOD; DIABETIC NEPHROPATHY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL INSUFFICIENCY; TRIGLYCERIDES;

EID: 84864083770     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.03.017     Document Type: Article

References (20)

1. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342:1792-1801.
2. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
3. Mertens I., Verrijken A., Michiels J.J., Van der Planken M., Ruige J.B., Van Gaal L.F. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006, 30:1308-1314.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
5. Bakris G., Vassalotti J., Ritz E., Wanner C., Stergiou G., Molitch M., et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 2010, 78:726-736.
6. Penno G., Solini A., Bonora E., Fondelli C., Orsi E., Zerbini G., et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011, 29:1802-1809.
7. Solini A., Penno G., Bonora E., Fondelli C., Orsi E., Arosio M., et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Care 2012, 35:143-149.
8. Ha H., Oh E.Y., Lee H.B. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009, 5:203-211.
9. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
10. Rerolle J.P., Hertig A., Nguyen G., Sraer J.D., Rondeau E.P. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000, 58:1841-1850.
11. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814-1818.
12. Seo J.Y., Park J., Yu M.R., Kim Y.S., Ha H., Lee H.B. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes. Am J Nephrol 2009, 30:481-490.
13. Brazionis L., Yau J., Rowley K., Itsiopoulos C., O'Dea K., Wong T.Y., et al. Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes. Diabetes Res Clin Pract 2010, 87:192-199.
14. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000, 49:633-639.
15. Alessi M.C., Poggi M., Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007, 18:240-245.
16. Brown N.J. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010, 4:315-324.
17. Li S.H., Lawrence D.A. Development of inhibitors of plasminogen activator inhibitor-1. Methods Enzymol 2011, 501:177-207.
18. Gupta A., Gupta P., Biyani M. Targeted therapies in diabetic nephropathy: an update. J Nephrol 2011, 24:686-695.
19. Shirakawa J., Fujii H., Ohnuma K., Sato K., Ito Y., Kaji M., et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011, 60:1246-1257.
20. Brazionis L., Rowley K., Jenkins A., Itsiopoulos C., O'Dea K. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol 2008, 28:786-791.